Kitov (NasdaqCM: KTOV) is a biopharmaceutical company focused of the development of therapeutic candidates for the treatment of pain associated with osteoarthritis. The Company’s lead product candidate is KIT-302, a fixed dose combination tablet comprised of the nonsteroidal anti-inflammatory (NSAID) celecoxib and the anti-hypertensive agent amlodipine besylate. It is being developed for patients with osteoarthritis and hypertension, and is intended to address an unmet need since physicians often avoid prescribing NSAIDs due to their hypertensive side effects. Results from a recently completed pivotal Phase III study demonstrated that KIT-302 significantly reduced blood pressure compared to amlodipine alone. Kitov intends to submit an NDA for KIT-302 in the second half of 2016.